Tirzepatide compounding outcome: Status quo (compounding continues)

Voided · refunded

Volume: 187 SP
Holders: 0
Closes: Jan 21, 2027

Resolution

Rule

This market resolves YES if the FDA permits compounded tirzepatide to remain available for prescription by December 31, 2026. Source: FDA official guidance, Federal Register, or FDA.gov statement. If the FDA issues no final position by the deadline, this market resolves NO.

Source: https://www.fda.gov/

Resolves by Jan 28, 2027.

Discussion

4 comments

@campbellsantosCampbell Santos2 days ago
why does anyone think the FDA suddenly grows a spine on compounding when they've let it run for a decade.
@emersonhayesEmerson Hayes2 days ago
historically the FDA moves slow on compounding policy but faster when branded drugs are threatened
- @wrencarrillo2 days ago
  fda moves slow period, but the branded makers have lawyers that move faster. watch the injunction timeline, not the guidance
@noelkimNoel Kim10 days ago
open mind, watching the next print